1Kurasawa, T, Chikaraishi, Y, Naito, A, et al. (2005) Effect of Humulus lupulus on gastric secretion in a rat pylorus-ligated model. Biol Pharm Bull 28, 353–357.
2Heyerick, A, Vervarcke, S, Depypere, H, et al. (2006) A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas 54, 164–175.
3Yamaguchi, N, Satoh-Yamaguchi, K & Ono, M (2009) In vitro evaluation of antibacterial, anticollagenase, and antioxidant activities of hop components (Humulus lupulus) addressing acne vulgaris. Phytomedicine 16, 369–376.
4Shimamura, M, Hazato, T, Ashino, H, et al. (2001) Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289, 220–224.
5Yasukawa, K, Takeuchi, M & Takido, M (1995) Humulone, a bitter in the hop, inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Oncology 52, 156–158.
6Yamamoto, K, Wang, J, Yamamoto, S, et al. (2000) Suppression of cylooxygenase-2 gene transcription by humulone of beer hop extract studies with reference to glucocorticoid. FEBS Lett 465, 103–106.
7Lee, JC, Kundu, JK, Hwang, DM, et al. (2007) Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-kB and AP-1: IκB kinase and c-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis 28, 1491–1498.
8Nozawa, N (2005) Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-Ay mice. Biochem Biophys Res Commun 336, 754–761.
9Colgate, EC, Miranda, CL, Stevens, JF, et al. (2007) Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett 246, 201–209.
10Mendes, V, Monterio, R, Pestana, D, et al. (2008) Xanthohumol influences preadipocyte differentiation: implication of antiproliferative and apoptotic effects. J Agric Food Chem 56, 11631–11637.
11Yajima, H, Ikeshima, E, Shiraki, M, et al. (2004) Isohumulones, bitter acids derived from hops, activate both peroxisome proliferators-activated receptor α and γ and reduce insulin resistance. J Biol Chem 279, 33456–33462.
12Yajima, H, Noguchi, T, Ikeshima, E, et al. (2005) Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents. Int J Obes 29, 991–997.
13Miura, Y, Hosono, M, Oyamada, C, et al. (2005) Dietary isohumulones, the bitter components of beer, raise plasma HDL-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARα activation in C57BL/6 mice. Br J Nutr 93, 559–567.
14Shimura, M, Hasumi, A, Minato, T, et al. (2005) Isohumulones modulate blood lipid status through the activation of PPARα. Biochim Biopys Acta 1736, 51–60.
15Obara, K, Mizutani, M, Hitomi, Y, et al. (2009) Isohumulones, the bitter component of beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes. Clin Nutr 28, 278–284.
16Namikoshi, T, Tomita, N, Fujimoto, S, et al. (2007) Isohumulones derived from hops ameliorate renal injury via an anti-oxidative effect in Dahl salt-sensitive rats. Hypertens Res 30, 175–184.
17Fletcher, MJ (1968) A colorimetric method for estimating serum triglycerides. Clin Chem Acta 22, 393–397.
18Zak, B, Dickman, RC, White, EG, et al. (1954) Rapid estimation of free and total cholesterol. Am J Clin Pathol 24, 1307–1315.
19Han, L-K, Takaku, T, Li, J, et al. (1999) Anti-obesity action of oolong tea. Int J Obesity 23, 98–105.
20Hagino, K, Oshige, H, Ozawa, K, et al. (1991) Effect of XKJ-001, a crude drug preparation, on body water distribution and water excretion in mice. Yakugaku Zasshi 111, 293–298.
21Novikoff, AB, Novikoff, PM, Rosen, OM, et al. (1980) Organelle relationships in cultured 3T3-L1 preadipocytes. J Cell Biol 87, 180–196.
22Flatt, JP (1987) The difference in the storage capacities for carbohydrate and for fat, and its implications in the regulation of body weight. Ann N Y Acad Sci 499, 104–123.
23Awad, AB, Bernardis, LL & Fink, CS (1990) Failure to demonstrate an effect of dietary fatty acid composition on body weight, body consumption and parameters of lipid metabolism in mature rats. J Nutr 120, 1277–1282.
24Shimomura, Y, Tamura, T & Suzuki, M (1990) Less body fat accumulation in rats fed a safflower oil diet than in rats fed a beef tallow diet. J Nutr 120, 1291–1296.
25Hill, JO, Peters, JC, Lin, D, et al. (1993) Lipid accumulation and body fat distribution is influenced by the type of dietary fed to rats. Int J Obes 17, 223–226.
26Plutzky, J (2000) Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 15, 416–421.
27Reaven, GM (1988) Role of insulin resistance on human disease. Diabetes 37, 1595–1607.
28Gordon, ES, Glodberg, M & Chosy, GJ (1963) A new concept in the treatment of obesity. JAMA 186, 50–60.
29Messerli, FH, Christie, B & De Carvalho, JGR (1981) Obesity and essential hypertension: hemodynamics, intravascular volume, sodium excretion and plasma renin activity. Arch Intern Med 141, 81–85.
30Rocchini, AP, Katch, V & Kvselis, D (1989) Insulin and renal sodium retension in obese adolescents. Hypertension 14, 367–374.
31Landberg, L (1992) Hyperinslinemia: possible role in obesity-induced hypertension. Hypertension 19, Suppl. 1, 61–66.
32Laragh, JH (1985) Atrial natriuretic hormone, the renine-aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med 313, 1330–1340.
33De Pergola, G, Garruti, G, Giorgino, F, et al. (1994) Reduced effectiveness of atrial natriuretic factor in pre-menopausal obese women. Int J Obes 18, 93–97.
34Valensi, P, Sibony-Prat, J, Behar, A, et al. (1997) Impairment of antidiuretic hormone and atrial natriuretic peptide regulation in the obese woman with a swelling syndrome and an increase in capillary permeability to albumin. Int J Obes 21, 651–657.
35Oosterveer, MH, van Dijk, TH, Tietge, UJF, et al. (2009) High fat feeding induces hepatic fatty acid elongation in mice. PLoS One 4, e6066.
36Kanh, BB & Flier, JS (2000) Obesity and insulin resistance. J Clin Invest 106, 473–481.
37Sumiyoshi, M, Sakanaka, M & Kimura, Y (2006) Chronic intake of high-fat and high-sucrose diets differentially affects glucose intolerance in mice. J Nutr 136, 582–587.
38Tontonoz, P, Hu, E & Spiegelman, BM (1994) Stimulation of adipogenesis in fibroblast by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147–1156.
39Evans, M, Park, Y, Pariza, M, et al. (2001) Trans-10, cis-12 conjugated linoleic reduces triglyceride content while differentially affecting peroxisome proliferator activated receptor gamma2 and aP2 expression in 3T3-L1 preadipocytes. Lipids 36, 1223–1232.
40Peterson, KF, Krssak, M, Inzucchi, S, et al. (2000) Mechanism of troglitazone action in type 2, diabetes. Diabetes 49, 827–831.
41Greene, DA (1999) Rosiglitazone: a new therapy for type 2 diabetes. Exp Opin Invest Drug 8, 1709–1719.
42Boden, G, Homko, C, Mozzoli, M, et al. (2005) Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54, 880–885.
43Lee, G, Elwood, F, McNally, J, et al. (2002) T007097, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277, 19649–19657.